Cargando…

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance

Detalles Bibliográficos
Autor principal:	Nishimura, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835558/ https://www.ncbi.nlm.nih.gov/pubmed/29396298 http://dx.doi.org/10.1016/j.ebiom.2018.01.019

Ejemplares similares

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

Identification of a clinical compound losmapimod that blocks Lassa virus entry
por: Zhang, Xiaoyu, et al.
Publicado: (2019)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2020)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

DRUG REPURPOSING—Overcoming the translational hurdles to clinical use
por: Martin, Jennifer H., et al.
Publicado: (2019)

Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod
por: Kragholm, Kristian, et al.
Publicado: (2015)

Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway
por: Li, Min, et al.
Publicado: (2019)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Antinociceptive properties of losmapimod in two acute pain models in rats: behavioural analysis, immunohistochemistry, dose response, and comparison with usual analgesic drugs()
por: Soued, Mickaël, et al.
Publicado: (2022)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells
por: Kim, Tae Woo, et al.
Publicado: (2023)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
por: Jeong, Inae, et al.
Publicado: (2019)

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021)

Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer
por: Wirth, Matthias
Publicado: (2022)

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
por: Chen, J, et al.
Publicado: (2013)

Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance
por: Yu, Xiwei, et al.
Publicado: (2015)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes
por: Pant, Ayush, et al.
Publicado: (2023)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
por: Meng, Jiao, et al.
Publicado: (2019)

MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition
por: Knight, Tristan E., et al.
Publicado: (2021)

FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1
por: Mellion, M., et al.
Publicado: (2020)

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer
por: Shuai, Shuai, et al.
Publicado: (2021)

Clinical trial data reuse – overcoming complexities in trial design and data sharing
por: Wilkinson, Toby, et al.
Publicado: (2019)

Overcoming physical barriers in cancer therapy
por: Beyer, Ines, et al.
Publicado: (2013)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry
por: Efficace, Fabio, et al.
Publicado: (2014)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms
por: Chen, Jiang, et al.
Publicado: (2020)

Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo
por: Yang, Sheng-Huei, et al.
Publicado: (2015)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
por: Jiang, Yuhong, et al.
Publicado: (2021)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
por: Liu, Yuhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_amta10ujb0gb0bnmo6jq824pqo